Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-07-14EMA Authorised: Ruxience (rituximab) — Pfizer Europe MA EEIG
The EMA authorised Ruxience, a rituximab biosimilar by Pfizer Europe MA EEIG, for several indications including chronic lymphocytic leukemia…
-
EMA approval · 2025-07-09EMA Authorised: Ituxredi (rituximab) — Reddy Holding GmbH
The EMA authorised Ituxredi (rituximab) by Reddy Holding GmbH. It is indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and r…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT [Phase 1]
Phase 1 trial evaluating multi-virus cytotoxic T lymphocytes engineered with CD19 chimeric receptors for CD19-positive malignancies after st…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 [Phase 2]
A Phase 2 clinical trial (CTRIAL-IE 07-01) for chronic lymphocytic leukemia conducted by Cancer Trials Ireland has completed. The document n…
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial evaluating human anti-CD19 CAR-T cells for relapsed or refractory lymphoid malignancies is currently active but not r…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL [Phase 1]
Phase 1 clinical trial evaluating autologous CD19-specific CAR T cells (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma, chronic …
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]
Phase 1 study update for CD19 CAR-allogeneic NKT therapy (ANCHOR) in relapsed or refractory B-cell malignancies; the trial is currently acti…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Allo HSCT Using RIC and PTCy for Hematological Diseases [Phase 2]
Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and post-transplan…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study [Phase 2]
Phase 2 DIRECT trial evaluating daratumumab with ibrutinib for relapsed or refractory chronic lymphocytic leukemia was terminated, with resu…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
Mayo Clinic is conducting a Phase 1 clinical trial evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
A completed UK trial evaluating changes in patient experience for adults with chronic lymphocytic leukemia treated with venetoclax plus ritu…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …
-
CLINICAL_TRIALS trial_result · 2025-06-22Clinical Trial Update: A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]
This update covers the completed Phase 1 study of the investigational drug JNJ-67856633 in participants with non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Time Restricted Eating in Haematological Malignancies [Phase 2]
A Phase 2 clinical trial update evaluating time-restricted eating in haematological malignancies, including chronic lymphocytic leukemia; th…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Economic Analysis of Alliance A041202 CLL Study
This document provides an economic analysis of the Alliance A041202 study in chronic lymphocytic leukemia, outlining cost-effectiveness cons…
-
FDA approval · 2025-06-10FDA Approved: BRUKINSA — Original Application (BeOne Medicines USA, Inc.)
The FDA approved the original application for Brukinsa (zanubrutinib) from BeOne Medicines USA, Inc., marking the U.S. approval of this BTK …
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) [Phase 2]
Phase 2 trial evaluating a sequential regimen of bendamustine debulking followed by venetoclax (ABT-199) and obinutuzumab (GA101) induction …
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS other · 2025-06-10Clinical Trial Update: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL [Phase 2]
Phase 2 clinical trial evaluating a sequential regimen of bendamustine, obinutuzumab, zanubrutinib, and venetoclax in relapsed/refractory ch…
-
CLINICAL_TRIALS trial_result · 2025-06-08Clinical Trial Update: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL [Phase 2]
Phase 2 study evaluating the efficacy of acalabrutinib in very old or frail patients with treatment-naïve or relapsed/refractory chronic lym…
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 study investigating the sequencing of pirtobrutinib after progression on first-line acalabrutinib in adults with chronic lymphocyt…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study [Phase 2]
A Phase II clinical trial evaluating ZGB (zanubrutinib, obinutuzumab, bendamustine) as first-line therapy for chronic lymphocytic leukemia; …
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
A two-stage Phase 1/2 trial evaluating RP-3500 in combination with Olaparib for DNA damage repair pathway-deficient relapsed/refractory chro…